Antihistamine Nasal Spray and COVID-19 Prevention: A Comprehensive Study

Welcome to another insightful update from MedCram. In this post, we will discuss the latest findings from a randomized clinical trial published in JAMA in September 2025, which explored the efficacy of azelastine nasal spray in preventing SARS-CoV-2 infections. This study sheds light on the potential of antihistamines in combating COVID-19 and could have implications for public health strategies moving forward.

Understanding Azelastine and Its Mechanism

Azelastine is an antihistamine that has shown promise in previous studies for its antiviral properties against SARS-CoV-2. Research conducted back in January 2021 identified azelastine and similar molecules as potential candidates for repurposing in the fight against COVID-19. The key to its effectiveness lies in its ability to bind to the sigma-1 receptor, which plays a crucial role in the entry of the virus into human cells.

The Recent Clinical Trial

The recent trial, known as the CONTAIN trial, was a phase 2 double-blind placebo-controlled study conducted in Germany with 450 healthy volunteers aged 18 to 65. Participants were randomly assigned to receive either 0.1% azelastine nasal spray or a placebo for 56 days, with the spray administered three times daily. The primary objective was to determine the incidence of SARS-CoV-2 infection by day 56.

Results of the Study

The results were promising. In the azelastine group, only 2.2% (5 out of 227) of participants contracted the virus, compared to 6.7% (15 out of 223) in the placebo group. This translates to a 69% reduction in the odds of infection for those using the nasal spray. Additionally, the duration of viral positivity was shorter in the azelastine group, indicating a potential benefit in reducing the severity of the disease.

Statistical Insights

The relative risk reduction of infection for those using the nasal spray was calculated to be 67.3%, while the absolute risk reduction stood at 4.53%. This means that to prevent one COVID-19 infection, approximately 23 individuals would need to use the nasal spray. This statistic emphasizes the potential impact of the nasal spray in larger populations, especially during surges in infection rates.

Safety and Side Effects

In terms of safety, the trial reported more adverse events in the placebo group than in the intervention group. Common side effects associated with azelastine included bitter taste, nosebleeds, and in rare cases, symptoms like tiredness and headaches. However, the overall safety profile was favorable, especially compared to the effects reported in the placebo group.

Practical Applications and Recommendations

Given these findings, the use of azelastine nasal spray may be beneficial in high-risk situations such as crowded places or during travel. However, continuous long-term use for COVID-19 prevention is not recommended due to insufficient data on potential long-term effects.

Conclusion

The CONTAIN trial provides promising evidence that azelastine nasal spray may serve as an effective prophylactic measure against SARS-CoV-2 infections. As we navigate ongoing challenges posed by COVID-19, such interventions could play a significant role in public health strategies. For those considering this treatment, consulting with a healthcare provider is essential.

For more detailed insights and future updates, be sure to subscribe to our channel and visit medcram.com.